
WHAT IS CLAIMED IS:

- 1. An intranasal formulation comprising scopolamine in a pharmaceutically acceptable carrier at a pH below about 4.0 and a buffer salt concentration below about 200 mM, said carrier incorporating polyvinyl alcohol.
- 2. An intranasal formulation as in claim 1, wherein said carrier is a pharmaceutically acceptable gel.
- 3. An intranasal formulation as in claim 1, wherein said polyvinyl alcohol is combined with one or more additional gelling agents or bio-adhesives selected from the group including alginates, gums, starches, polyacrylates, dextrans, chitosans and mixtures thereof.
- 4. An intranasal formulation as in claim 1, wherein said concentration is at or below about 100 mM.
- 5. An intranasal formulation as in claim 1, wherein said concentration is at or below about 50 mM.
- 6. An intranasal formulation as in claim 1, wherein said pH is about 3.5.
- 7. An intranasal formulation as in claim 1, wherein said scopolamine is provided as a chemically modified equivalent or pharmaceutically acceptable salt thereof.
- 8. An intranasal formulation as in claim 7, wherein said scopolamine is provided as scopolamine hydrobromide.
- 9. An intranasal formulation for preventing and/or treating nausea and/or vomiting described in claim 1.



- 10. An intranasal formulation as in claim 1 further including buffering agents, thickening agents, tolerance enhancers, surfactants, excipients, preservatives and combinations thereof.
- 11. An intranasal gel formulation for preventing and/or treating motion sickness comprising scopolamine hydrobromide in a gel solution at or below a pH at about 3.5 and a buffer salt concentration at or below about 100 mM, said gel solution incorporating polyvinyl alcohol as a gelling agent.
- 12. An intranasal formulation as in claim 11, wherein said gel solution further includes gelling agents and/or bio-adhesives selected from the group including alginates, gums, starches, polyacrylates, dextrans, chitosans and mixtures thereof.
- 13. An intranasal gel formulation as in claim 11 further including buffering agents, thickening agents, tolerance enhancers, surfactants, excipients, preservatives and combinations thereof.
- 14. A method of preventing and/or treating nausea and/or vomiting comprising administering intranasally to a mammal an effective amount of scopolamine, chemically modified equivalents and pharmaceutical salts thereof in a pharmaceutically acceptable carrier at a pH below about 40 and a buffer salt concentration below about 200 mM, said carrier incorporating polyvinyl alcohol.
- 15. A method as in claim 14, wherein said carrier further includes gelling agents and/or bio-adhesives selected from the group including alginates, gums, starches, polyacrylates, dextrans, chitosans and mixtures thereof.
- 16. A method as in claim 14, wherein said carrier is a gel for intranasal administration.



17. A method as in claim 14, wherein said salt concentration is at or below about 100 mM.

Sul03

- 18. A method as in claim 14, wherein said salt concentration is at or below about 50 mM.
- 19. A method as in claim 14, wherein said pH is about 3.5.
- 20. A method as in claim 14, wherein said scopolamine is provided as scopolamine hydrobromide.
- 21. A method as in claim 14, wherein a nausea and/or vomiting preventing or treating scopolamine free base plasma concentration is achieved within about 5 minutes.

ada c3/